Business Wire

CGTN

19.8.2020 14:12:04 CEST | Business Wire | Press release

Share
CGTN: Xi Jinping conducts inspection tour in flood-hit Anhui Province

Chinese President Xi Jinping arrived in east China's Anhui Province for an inspection tour on Tuesday.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200819005372/en/

Xi, also general secretary of the Communist Party of China Central Committee, visited the floodgate of the Wangjiaba Dam on the Huaihe River and other flood-hit areas in Funan County, Fuyang City. He also went to a "zhuangtai," a residential structure built on raised ground at a higher elevation that functions as a haven from river floods.

Since June, Anhui has been ravaged by floods and landslides caused by incessant heavy rains.

The president also met with local officials and residents and learned about flood prevention and disaster relief work and the progress of recovery efforts.

This is President Xi's latest inspection tour this year, following his visits to Yunnan Province , Beijing Municipality , Hubei Province , Zhejiang Province , Shaanxi Province , Shanxi Province , Ningxia Hui Autonomous Region and Jilin Province .

People-centered efforts

"I have always been concerned about the people in flood-stricken areas," Xi said while meeting locals, adding that he felt ease after seeing villagers had a place to live and had restarted production.

Severe rainstorms have hit many regions in China this summer, triggering flooding of rivers. According to the Ministry of Emergency Management (MEM), 54.8 million people in 27 provincial-level regions have been affected.

Chinese leaders have called for unrelenting efforts to ensure the safety of people's lives and property.

During a CPC leadership meeting on July 17, President Xi stressed putting people's lives and property first and taking more forceful measures to do well in flood control and relief work.

China has made all-out efforts in flood control and disaster relief with massive mobilization, evacuations and a top-level emergency response in several hard-hit provinces.

Through the nationwide joint efforts, the MEM said, the number of deaths and missing due to floods fell by 53.9 percent from with the national average of the past five years. The number of evacuated people increased by 36.7 percent, the ministry added.

Enhance capabilities to cope with natural disasters

Noting that China has fought against natural disasters for thousands of years, Xi on Tuesday also urged respect for nature, harmony between humans and nature and efforts to improve capabilities to cope with natural disasters.

"We should modernize our ability to prevent and combat natural disasters in our effort to build a modern socialist country in an all-round way," Xi added.

Hailed as the "most important floodgate on the Huaihe River," the floodgate of the Wangjiaba Dam sets a good example of China's flood preparation.

The floodgate, built in 1953 was opened for the 16th time on July 20 to store water, intercepting 375 million cubic meters of potential floodwater by July 23 when it was closed.

The CPC leadership meeting on July 17 also stressed that China needs to comprehensively enhance its disaster prevention capability and will include capacity building on disaster prevention in its 14th Five-Year Plan covering the period 2021-2025.

Social Media:

https://www.facebook.com/ChinaGlobalTVNetwork/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye